Shares of Fusion Pharmaceuticals Rise 7.8% With Study Protocol Aligment Reached
05 1월 2024 - 8:53AM
Dow Jones News
By Ben Glickman
Shares of Fusion Pharmaceuticals rose in post-market trading on
Thursday after the company had a study protocol approved by
regulators.
The stock was up 7.8% to $9.10, after it closed the market
session up 6.8%. Shares have more than doubled in the last three
months.
The company, which is focused on the development of oncology
drugs, said it had aligned with the Food and Drug Administration on
its Phase 2/3 protocol for FPI-2265, a treatment for certain kinds
of prostate cancer. The updated development plan includes a Phase 2
dose optimization lead-in and a Phase 3 registrational trial, which
is expected to begin in 2025.
The treatment is a targeted alpha therapy that will be evaluated
for use in patients with metastatic castration-resistant prostate
cancer with progressive disease.
Chief Executive John Valliant said the plan outlined a path for
bringing the therapy to market, if approved.
Fusion said it had also produced its first clinical dose at its
proprietary manufacturing facility.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 04, 2024 18:38 ET (23:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Fusion Pharmaceuticals (NASDAQ:FUSN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Fusion Pharmaceuticals (NASDAQ:FUSN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
